<DOC>
	<DOCNO>NCT01721876</DOCNO>
	<brief_summary>To investigate efficacy , safety , pharmacokinetics intravenous volasertib + subcutaneous low dose cytarabine patient &gt; = 65 year age previously untreated acute myeloid leukaemia , ineligible intensive remission induction therapy</brief_summary>
	<brief_title>Volasertib Combination With Low-dose Cytarabine Patients Aged 65 Years Above With Previously Untreated Acute Myeloid Leukaemia , Who Are Ineligible Intensive Remission Induction Therapy ( POLO-AML-2 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Inclusion criterion : 1 . Age &gt; = 65years . 2 . Cytologically/histologically confirm acute myeloid leukaemia ( AML ) accord WHO classification ; ( except acute promyelocytic leukaemia ( APL ) . 3 . Previously untreated AML ( except hydroxyurea and/or corticosteroid therapy 28 day ( cumulative ) ) . Previous therapy Myelodysplastic Syndrome ( MDS ) allow . 4 . Investigator considers patient ineligible intensive remission induction therapy base document medical reason ( e.g . disease characteristic like AML genetics , type AML ( de novo secondary ) , patient characteristic like performance score , concomitant diagnosis , organ dysfunction ) . 5 . Patient eligible LowDose Cytarabine ( LDAC ) treatment . 6 . Eastern cooperative oncology group ( ECOG ) performance score &lt; = 2 screening . 7 . Signed date write informed consent start date Screening visit accordance Good Clinical Practice ( GCP ) local legislation . Exclusion criterion : 1 . Prior concomitant chemotherapy AML ( exception hydroxyurea and/or corticosteroid therapy 28 day ( cumulative ) ) . Please note prior therapy MDS allow . 2 . Treatment investigational drug within 2 week first administration present trial drug . 3 . Acute promyelocytic leukaemia ( FrenchAmericanBritish ( FAB ) classification subtype M3 ) . 4 . Current clinical central nervous system ( CNS ) symptom deem investigator related leukaemic CNS involvement ( lumbar puncture require , clinical assessment per investigator´s judgement sufficient ) . 5 . Hypersensitivity one trial drug excipients . 6 . Severe illness organ dysfunction involve heart , kidney , liver organ system ( e.g . active infection , clinically relevant impairment cardiac function , severe heart failure/cardiac insufficiency , unstable angina pectoris history recent myocardial infarction ) , opinion investigator precludes treatment LDAC . 7 . Corrected QT interval accord Fridericia ( QTcF ) prolongation &gt; 470 m QT prolongation deem clinically relevant investigator ( e.g. , congenital long QT syndrome ) .The QTcF calculate mean 3 Electrocardiogram ( ECGs ) take screening . 8 . Total bilirubin &gt; 3 x upper limit normal ( ULN ) . 9 . Creatinine clearance ( CLcr ) &lt; 30 ml/min ( estimate creatinine clearance CockcroftGault ( CG ) equation ) . 10 . Active hepatitis B hepatitis C , laboratory evidence chronic infection . 11 . HIV infection . 12 . Second malignancy currently require active therapy ( except hormonal/antihormonal treatment e.g . prostate breast cancer ) . 13 . Any significant concurrent psychiatric disorder social situation accord investigator´s judgement would compromise patient´s safety compliance , interfere consent , study participation , interpretation study result . 14 . Known suspect active alcohol drug abuse . 15 . Patient unable comply protocol , opinion investigator . 16 . Male patient partner childbearing potential unwilling use condom combination second medically acceptable method contraception trial minimum 6 month study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>